Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Rallybio Corp
13G/A
Amendment 1
RLYB · 75120L209
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 0% | ||||
| Bihua Chen | 0% | ||||
|
Rapport Therapeutics, Inc.
13G/A
Amendment 5
RAPP · 75383L102
|
5.6% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 5.6% | ||||
| Bihua Chen | 5.6% | ||||
|
Quince Therapeutics, Inc.
13G
IRLA · 22053A305
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
MoonLake Immunotherapeutics
13G/A
Amendment 2
MLTX · 61559X104
|
4.4% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 4.4% | ||||
| Bihua Chen | 4.4% | ||||
|
iBio, Inc.
13G/A
Amendment 2
IBIO · 451033708
|
10.0% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
EyePoint, Inc.
13G/A
Amendment 4
EYPT · 30233G209
|
8.4% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 8.4% | ||||
| Bihua Chen | 8.4% | ||||
|
Bright Minds Biosciences Inc.
13G/A
Amendment 4
DRUG · 10919W405
|
9.2% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 9.2% | ||||
| Bihua Chen | 9.2% | ||||
|
Cabaletta Bio, Inc.
13G/A
Amendment 4
CABA · 12674W109
|
6.0% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 6.0% | ||||
| Bihua Chen | 6.0% | ||||
|
BioAge Labs, Inc.
13G/A
Amendment 4
BIOA · 09077V100
|
5.4% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 5.4% | ||||
| Bihua Chen | 5.4% | ||||
|
Adlai Nortye Ltd.
13G/A
Amendment 1
ANL · 00704R109
|
6.8% |
8/14/2026
Event 6/30/2026
|
|||
| Cormorant Asset Management, LP | 6.8% | ||||
| Bihua Chen | 6.8% | ||||
|
BlossomHill Therapeutics, Inc.
13D
BLSM · 095130100
|
11.8% |
8/13/2026
Event 8/6/2026
|
|||
| Cormorant Global Healthcare Master Fund, LP | 3.1% | ||||
| Cormorant Global Healthcare GP, LLC | 3.1% | ||||
| Cormorant Private Healthcare Fund III, LP | 4.0% | ||||
| Cormorant Private Healthcare GP III, LLC | 4.0% | ||||
| Cormorant Private Healthcare Fund V, LP | 3.4% | ||||
| Cormorant Private Healthcare GP V, LLC | 3.4% | ||||
| Cormorant Private Healthcare Fund VI, LP | 1.2% | ||||
| Cormorant Private Healthcare GP VI, LLC | 1.2% | ||||
| Cormorant Asset Management, LP | 11.8% | ||||
| Chen Bihua | 11.8% | ||||
|
Rallybio Corp
13G
RLYB · 75120L209
|
7.6% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 7.6% | ||||
| Bihua Chen | 7.6% | ||||
|
Rapport Therapeutics, Inc.
13G/A
Amendment 4
RAPP · 75383L102
|
6.2% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 6.2% | ||||
| Bihua Chen | 6.2% | ||||
|
MoonLake Immunotherapeutics
13G/A
Amendment 1
MLTX · 61559X104
|
6.3% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 6.3% | ||||
| Bihua Chen | 6.3% | ||||
|
iBio, Inc.
13G/A
Amendment 1
IBIO · 451033708
|
10.0% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
Cabaletta Bio, Inc.
13G/A
Amendment 3
CABA · 12674W109
|
9.0% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 9.0% | ||||
| Bihua Chen | 9.0% | ||||
|
BioAge Labs, Inc.
13G/A
Amendment 3
BIOA · 09077V100
|
6.5% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 6.5% | ||||
| Bihua Chen | 6.5% | ||||
|
Adlai Nortye Ltd.
13G
ANL · 00704R109
|
5.2% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 5.2% | ||||
| Bihua Chen | 5.2% | ||||
|
Agomab Therapeutics NV
13G
AGMB · 00860C102
|
5.0% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 5.0% | ||||
| Bihua Chen | 5.0% | ||||
|
enGene Holdings Inc.
13G/A
Amendment 1
ENGN · 29286M105
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| Cormorant Asset Management, LP | 0% | ||||
| Bihua Chen | 0% | ||||
|
Bright Minds Biosciences Inc.
13G/A
Amendment 3
DRUG · 10919W405
|
9.7% |
4/30/2026
Event 4/28/2026
|
|||
| Cormorant Asset Management, LP | 9.7% | ||||
| Chen Bihua | 9.7% | ||||
|
BioAge Labs, Inc.
13G/A
Amendment 2
BIOA · 09077V100
|
5.7% |
2/17/2026
Event 12/31/2025
|
|||
| Cormorant Asset Management, LP | 5.7% | ||||
| Bihua Chen | 5.7% | ||||
|
Rapport Therapeutics, Inc.
13G/A
Amendment 3
RAPP · 75383L102
|
6.4% |
2/17/2026
Event 12/31/2025
|
|||
| Cormorant Asset Management, LP | 6.4% | ||||
| Bihua Chen | 6.4% | ||||
|
MoonLake Immunotherapeutics
13G
MLTX · 61559X104
|
6.1% |
2/17/2026
Event 12/31/2025
|
|||
| Cormorant Asset Management, LP | 6.1% | ||||
| Bihua Chen | 6.1% | ||||
|
enGene Holdings Inc.
13G
ENGN · 29286M105
|
6.0% |
2/17/2026
Event 12/31/2025
|
|||
| Cormorant Asset Management, LP | 6.0% | ||||
| Bihua Chen | 6.0% | ||||
|
Cabaletta Bio, Inc.
13G/A
Amendment 2
CABA · 12674W109
|
9.3% |
2/17/2026
Event 12/31/2025
|
|||
| Cormorant Asset Management, LP | 9.3% | ||||
| Bihua Chen | 9.3% | ||||
|
Bright Minds Biosciences Inc.
13G/A
Amendment 2
DRUG · 10919W405
|
10.9% |
2/6/2026
Event 1/31/2026
|
|||
| Cormorant Asset Management, LP | 10.9% | ||||
| Bihua Chen | 10.9% | ||||
|
Corbus Pharmaceuticals Holdings, Inc.
13G/A
Amendment 4
CRBP · 21833P301
|
13.4% |
12/15/2025
Event 12/11/2025
|
|||
| Cormorant Asset Management, LP | 13.4% | ||||
| Chen Bihua | 13.4% | ||||
|
EyePoint Pharmaceuticals, Inc.
13G/A
Amendment 3
EYPT · 30233G209
|
10.0% |
12/8/2025
Event 12/4/2025
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Chen Bihua | 10.0% | ||||
|
Corbus Pharmaceuticals Holdings, Inc.
13G/A
Amendment 3
CRBP · 21833P301
|
12.8% |
11/14/2025
Event 11/3/2025
|
|||
| Cormorant Asset Management, LP | 12.8% | ||||
| Bihua Chen | 12.8% | ||||
|
Cabaletta Bio, Inc.
13G/A
Amendment 1
CABA · 12674W109
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
VYNE Therapeutics Inc.
13G/A
Amendment 4
VYNE · 92941V308
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Cormorant Asset Management, LP | 0% | ||||
| Bihua Chen | 0% | ||||
|
Rapport Therapeutics, Inc.
13G/A
Amendment 2
RAPP · 75383L102
|
6.7% |
11/14/2025
Event 9/30/2025
|
|||
| Cormorant Asset Management, LP | 6.7% | ||||
| Bihua Chen | 6.7% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 6
PRAX · 74006W207
|
4.0% |
11/14/2025
Event 9/30/2025
|
|||
| Cormorant Asset Management, LP | 4.0% | ||||
| Bihua Chen | 4.0% | ||||
|
KALA BIO, Inc.
13G/A
Amendment 1
KALA · 483119202
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Cormorant Asset Management, LP | 0% | ||||
| Bihua Chen | 0% | ||||
|
iBio, Inc.
13G
IBIO · 451033708
|
10.0% |
11/14/2025
Event 9/30/2025
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
Biomea Fusion, Inc.
13D/A
Amendment 4
BMEA · 09077A106
|
1.5% |
10/24/2025
Event 10/22/2025
|
|||
| Cormorant Global Healthcare Master Fund, LP | 0.7% | ||||
| Cormorant Global Healthcare GP, LLC | 0.7% | ||||
| Cormorant Private Healthcare Fund III LP | 0.7% | ||||
| Cormorant Private Healthcare GP III, LLC | 0.7% | ||||
| Cormorant Asset Management, LP | 1.4% | ||||
| Chen Bihua | 1.5% | ||||
|
Biomea Fusion, Inc.
13D/A
Amendment 3
BMEA · 09077A106
|
5.3% |
10/10/2025
Event 10/8/2025
|
|||
| Cormorant Global Healthcare Master Fund, LP | 2.6% | ||||
| Cormorant Global Healthcare GP, LLC | 2.6% | ||||
| Cormorant Private Healthcare Fund III LP | 2.5% | ||||
| Cormorant Private Healthcare GP III, LLC | 2.5% | ||||
| Cormorant Asset Management, LP | 5.2% | ||||
| Chen Bihua | 5.3% | ||||
|
VYNE Therapeutics Inc.
13G/A
Amendment 3
VYNE · 92941V308
|
8.2% |
8/14/2025
Event 6/30/2025
|
|||
| Cormorant Asset Management, LP | 8.2% | ||||
| Bihua Chen | 8.2% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 5
PRAX · 74006W207
|
7.7% |
8/14/2025
Event 6/30/2025
|
|||
| Cormorant Asset Management, LP | 7.7% | ||||
| Bihua Chen | 7.7% | ||||
|
Cabaletta Bio, Inc.
13G
CABA · 12674W109
|
5.5% |
8/14/2025
Event 6/30/2025
|
|||
| Cormorant Asset Management, LP | 5.5% | ||||
| Bihua Chen | 5.5% | ||||
|
BioAge Labs, Inc.
13G/A
Amendment 1
BIOA · 09077V100
|
6.0% |
8/14/2025
Event 6/30/2025
|
|||
| Cormorant Asset Management, LP | 6.0% | ||||
| Bihua Chen | 6.0% | ||||
|
Biomea Fusion, Inc.
13D/A
Amendment 2
BMEA · 09077A106
|
6.5% |
7/22/2025
Event 6/20/2025
|
|||
| Cormorant Global Healthcare Master Fund, LP | 3.2% | ||||
| Cormorant Global Healthcare GP, LLC | 3.2% | ||||
| Cormorant Private Healthcare Fund III LP | 3.0% | ||||
| Cormorant Private Healthcare GP III, LLC | 3.0% | ||||
| Cormorant Asset Management, LP | 6.3% | ||||
| Chen Bihua | 6.5% | ||||
|
OnKure Therapeutics, Inc.
13G/A
Amendment 2
OKUR · 68277Q105
|
0% |
5/19/2025
Event 5/15/2025
|
|||
| Cormorant Asset Management, LP | 0% | ||||
| Bihua Chen | 0% | ||||
|
VYNE Therapeutics Inc.
13G/A
Amendment 2
VYNE · 92941V308
|
10.0% |
5/19/2025
Event 3/31/2025
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
VYNE Therapeutics Inc.
13G/A
Amendment 1
VYNE · 92941V308
|
0% |
5/15/2025
Event 3/31/2025
|
|||
| Cormorant Asset Management, LP | 0% | ||||
| Bihua Chen | 0% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 4
PRAX · 74006W207
|
8.6% |
5/15/2025
Event 3/31/2025
|
|||
| Cormorant Asset Management, LP | 8.6% | ||||
| Bihua Chen | 8.6% | ||||
|
CARGO Therapeutics, Inc.
13G
CRGX · 14179K101
|
7.3% |
5/15/2025
Event 3/31/2025
|
|||
| Cormorant Asset Management, LP | 7.3% | ||||
| Bihua Chen | 7.3% | ||||
|
Praxis Precision Medicines, Inc.
13G/A
Amendment 3
PRAX · 74006W207
|
9.1% |
2/14/2025
Event 12/31/2024
|
|||
| Cormorant Asset Management, LP | 9.1% | ||||
| Bihua Chen | 9.1% | ||||
|
KALA BIO, Inc.
13G
KALA · 483119202
|
10.0% |
2/14/2025
Event 12/31/2024
|
|||
| Cormorant Asset Management, LP | 10.0% | ||||
| Bihua Chen | 10.0% | ||||
|
BioAge Labs, Inc.
13G
BIOA · 09077V100
|
7.3% |
2/14/2025
Event 12/31/2024
|
|||
| Cormorant Asset Management, LP | 7.3% | ||||
| Bihua Chen | 7.3% | ||||